LIPID MEDIATORS IN IMMUNE REGULATION AND RESOLUTION by Gilroy, D W & Bishop-Bailey, D
  
RVC OPEN ACCESS REPOSITORY – COPYRIGHT NOTICE 
 
This author’s accepted manuscript may be used for non-commercial purposes in accordance 
with Wiley Terms and Conditions for Self-Archiving. 
The full details of the published version of the article are as follows: 
 
TITLE: LIPID MEDIATORS IN IMMUNE REGULATION AND RESOLUTION 
AUTHORS: Derek W. Gilroy, David Bishop‐Bailey 
JOURNAL: British Journal of Pharmacology 
PUBLISHER: Wiley 
PUBLICATION DATE: 23 January 2019 (online) 
DOI: https://doi.org/10.1111/bph.14587  
 LIPID MEDIATORS IN IMMUNE REGULATION AND RESOLUTION 
 
 
 
 
 
 
 
 
 
 
Derek W Gilroy and David Bishop-Bailey 
 
 
 
 
DWG: Centre for Clinical Pharmacology and Therapeutics, Division of Medicine, 5 
 
University Street, University College London, London WC1E 6JJ, UK. 
 
DBB:  Comparative  Biological  Sciences,  Royal  Veterinary  College,  University  of 
 
London, Royal College Street, London NW1 0TU, UK. 
 
 
 
 
Address correspondence to DWGilroy. E-mail d.gilroy@ucl.ac.uk; fax +020-7679- 
 
6351 
 
 
 
 
 
 
 
KEYWORDS:  arachidonic  acid,  polyunsaturated  fatty  acids,  eicosanoids, 
prostanoids,  leukotrienes,  lipoxins,  epoxyeicosatrienoic  acids,  docosahexaenoic 
acid, resolvins, protectins, maresins, cytochrome p450. 
 
 
 
 
 
 
Running title: Lipids in inflammation 
 
The authors have no competing interests 
 
 
This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process which may 
lead to differences between this version and the Version of Record. Please cite this article as 
doi: 10.1111/bph.14587 
 ABSTRACT 
 
We are all too familiar with the events that follow a bee sting  – heat, redness, 
swelling and pain. These are Celsus’ four cardinal signs of inflammation that are 
driven by very well defined signals and hormones; in fact targeting the factors that 
drive this onset phase is the basis upon which most current anti-inflammatory 
therapies were developed. We are also very well aware that within a few hours these 
cardinal signs normally disappear. In other words, inflammation resolves. When it 
does not, inflammation persists resulting in damaging chronic conditions. While 
inflammatory onset is actively driven so also is its resolution – years of research has 
identified novel internal counter-regulatory signals that work together to switch off 
inflammation.  Among  these  signals,  lipids  are  potent  signaling  molecules  that 
regulate an array of immune responses including vascular hyper reactivity and pain 
as well as leukocyte trafficking and clearance, so-called resolution. Here, we collate 
bioactive lipid research to date and summarise the major pathways involved in their 
biosynthesis and their role in inflammation as well as resolution. 
 ABBREVIATIONS 
 
 
Arachidonic acid (AA) 
Cyclooxygenase (COX) 
Thromboxane A synthase (TXAS) 
Prostaglandin D synthase (PGDS) 
Prostaglandin E synthase (PGES-1, -2 and -3) 
Prostaglandin F synthase (PGFS) 
Resolvins (Rvs)  
Protectins (PDs) 
IκB kinase (IKK), 
Cytochrome P450 (CYP450) 
 
Soluble (sEH) and microsomal (mEH) epoxide hydrolase’s 
 
Dihydroxy-eicosatrienoic acids (DHETs). 
 
Intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 
(VCAM-1) 
 
Cysteinyl leukotriene receptor 1 and 2 (cys-LT1 and cys-LT2). 
Lipoxins (LXs) 
15 epimeric-LX (15-epi-LXs) or aspirin-trigged LXs (ATL) 
 
18R-hydroxyeicosapentanoic acid (18R-HEPE) 
Eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) 
Omega-3 polyunsaturated fatty acids (ω3-PUFA), 
Resolvin D1 (RvD1) 
Protectin D1 (PD1) 
Neuroprotectin D1 (NPD1). 
14S-hydroperoxydocosahexaenoic acid (14S-HPDHA; maresin, MaR1) 
Maresins (MaR) 
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 INFLAMMATION AND ITS RESOLUTION 
 
 
Inflammation is a protective response against infection and/or injury. However, when 
it becomes dysregulated as a consequence of genetic abnormalities, the ageing 
process or environmental factors, our immune system has the capacity to cause 
extensive damage. Arthritis, asthma, chronic obstructive pulmonary disease, 
Alzheimer’s disease, atherosclerosis and even cancer, while aetiologically disparate, 
are diseases unified by a dysregulated immune component. The current strategy of 
treating such diseases is based, largely, upon inhibiting the factors that drive acute 
inflammation such as nonsteroidal anti-inflammatory drugs (NSAIDS  - naproxen, 
 
diclofenac, etc), steroids (Prednisone) and ‘biologic’ drugs such as  Infliximab (anti- 
TNF) and Anakinra (anti-IL-1). Although these medicines ameliorate disease 
symptoms they do not bring about a ‘cure’ and are ineffective in a significant subset 
of patients. Furthermore, side effects can hamper endogenous homeostatic systems, 
predisposing  to  infection.  Thus,  there  is  a  need  to  develop  more  efficient  and 
effective therapeutics; with one approach being to harness the bodies own healing 
process for therapeutic gain. 
 
 
 
 
 
Consequently, attention has turned to the other end of the inflammatory spectrum, 
resolution, in order to understand the endogenous processes that switch off 
inflammation. Our objective has been to identify novel internal counter-regulatory 
systems that terminate inflammation in order to provide new targets that can be 
harnessed pharmacologically to push on-going inflammation down a pro-resolution 
pathway. Consequently, resolution is now been studied in great detail with clear 
evidence suggesting that resolution is an active process with quantifiable indices and 
 specific requirements. Along these lines, lipid mediators have emerged as internal 
regulatory signals that activate many aspect of the inflammation/resolution cascade 
including terminating leukocyte trafficking into tissue once the inflammatory signal 
has been removed, scavenging pro-inflammatory signals as well as clearing dead 
cells from the resolves site.  Hence, in this review the role of lipids in the resolution 
cascade will be discussed. 
 
 
 
 
CYCLOOXYGENASE AND PROSTANOIDS 
 
Cyclooxygenase  (COX)  converts  arachidonic  acid  (AA)  to  form  PGG2   (Pagels, 
Sachs, Marnett, Dewitt, Day & Smith, 1983) with the peroxidase element of the 
enzyme further reducing PGG2 to PGH2 (Hamberg & Samuelsson, 1973), which 
serves as a precursor for all major prostanoid mediators. There are two principle 
isoforms involved in the conversion of AA to prostanoids, namely COX-1 and COX-2. 
Unlike COX-1, which is constitutively expressed in most cells and tissues and is 
broadly involved in house-keeping functions, COX-2 is induced in response to 
inflammatory (Dubois et al., 1998) being expressed at sites of infection and injury 
with  the  exception  of  parts  of  the  brain  and  kidney  (Harris,  McKanna,  Akai, 
Jacobson, Dubois & Breyer, 1994). Formation of prostanoids from PGH2 occurs 
through the actions of downstream synthases that are expressed in a tissue and cell 
type-selective fashion including prostaglandin D synthase (PGDS) (Shimizu, 
Yamamoto  &  Hayaishi,  1982)  prostaglandin  E  synthase  (PGES-1,  -2  and  -3) 
(Tanaka, Ward & Smith, 1987), prostaglandin F synthase (PGFS) (Hayashi, Fujii, 
Watanabe, Urade & Hayaishi, 1989), prostaglandin I synthase (PGIS), and 
thromboxane A synthase (TXAS) (Ullrich & Haurand, 1983), which form PGD2,  PGE2, 
 PGF2α  , PGI2  (also known as prostacyclin) and TXA2, respectively. The differential 
expression of these downstream enzymes within cells determines the profile and 
levels of prostanoid production generated under resting and inflammatory conditions. 
 
 
 
Presently there are nine known prostanoid receptors in mice and man. These include 
the PGD receptors DP1 and DP2, the PGE2 receptors, EP1, EP2, EP3 and EP4; the 
PGF receptor, FP; the PGI receptor, IP; and the TXA receptor, TP. In addition, there 
are splice variants of the EP3, FP and TP receptors differentiated only in their C- 
terminal  tails.  All  of  these  receptors  belong  to  the  G-protein  coupled  receptor 
(GPCR) superfamily of proteins, with the exception of DP2 (also known as CRTH2), 
which is a member of the chemoattractant receptor family (Hirai et al., 2001). The IP, 
DP1, EP2 and EP4 receptors signal through Gs resulting in an increased intracellular 
cAMP, whereas the EP3 receptor couples to Gi to reduce cAMP, while EP1, FP and 
TP receptors signal through Gq to induce calcium mobilization. 
 
 
 
The more common prostanoids, PGE2 and PGI2, both enhance vasodilation (Kaley, 
Hintze, Panzenbeck & Messina, 1985), oedema formation and vascular permeability 
particularly in the presence of histamine, bradykinin and 5-HT (Hata & Breyer, 2004). 
Mice that are genetically depleted for their respective receptors (IP, EP2 and EP3) 
show reduced pleural exudation following treatment with inflammogens including 
carrageenan and zymosan (Yuhki et al., 2004). 
 
 
 
Robust evidence from EP-deficient mice has shown that the febrile response to 
PGE2 arises from the actions of PGE2 on its EP3 receptor, which is present on 
sensory neurons in the periphery and brain (Dantzer, Konsman, Bluthe & Kelley, 
 2000). Equally, PGE2 is a potent pyretic agents known with elevated concentrations 
found in cerebrospinal fluid taken from patients with bacterial or viral infections 
(Saxena, Beg, Singhal & Ahmad, 1979). While none of the prostanoids cause pain 
directly, PGI2 and PGE2 reduce the threshold of nociceptor sensory neurons to 
stimulation when bound to IP, EP1, EP3 and EP4 receptors, respectively (Ahmadi, 
Lippross, Neuhuber & Zeilhofer, 2002). 
 
 
 
Prostanoids  also  play an  important  role  in protecting against  oxidative  injury  in 
cardiac tissue and in maintaining cardiovascular (CV) homeostasis. Indeed, their 
protective effect has been demonstrated in clinical studies, which found an increase 
risk of myocardial infarction (MI), stroke, systemic and pulmonary hypertension, 
thrombosis and sudden cardiac death following the use of COX-2 specific inhibitors 
(Garcia Rodriguez, Tacconelli & Patrignani, 2008). Furthermore, deleting specific 
prostanoid  synthases  and  receptors  result  in  an  augmentation  of 
ischemia/reperfusion injury (Xiao et al., 2001) as well as contributing to the decline in 
cardiac function following MI. CV health is regulated by vasodilatory PGI2  and pro- 
thrombotic TXA2 (Bunting, Moncada & Vane, 1983), where PGI2 counterbalance the 
actions of TXA2 (Grosser, Fries & FitzGerald, 2006). Indeed, endothelial PGI2 along 
with NO prevent TXA2-induced platelet aggregation and thrombosis. TXA2 is derived 
from platelet COX-1 causing platelet aggregation and vascular smooth muscle 
contraction (Ellis et al., 1976). Clinical CV diseases including unstable angina, MI 
and stroke can arise from overproduction of TXA4. Importantly, the cardio-protective 
properties of aspirin can be attributed to the covalent inhibition of COX-1 (Rocca et 
al., 2002). 
 As well as being pro-inflammatory, many prostanoids upregulate intracellular cAMP 
triggering immuno-suppressive effects. For example, PGE2  and PGI2  reduce the 
ability of inflammatory leukocytes to phagocytose and kill microorganisms (Aronoff, 
Canetti & Peters-Golden, 2004), as well as inhibit the production of downstream pro- 
inflammatory mediators (Aronoff et al., 2007) while, in contrast, triggering the 
synthesis of IL-10 and IL-6 (Harizi, Juzan, Pitard, Moreau & Gualde, 2002). Indeed, 
in a number of conditions associated with increased susceptibility to infection, 
including cancer (Starczewski, Voigtmann, Peskar & Peskar, 1984), aging (Hayek et 
al., 1997) and cystic fibrosis (Medjane, Raymond, Wu & Touqui, 2005) 
overexpression  of  PGE2   has  been  reported.  Interestingly,  during  the  very  early 
phase  of  acute  inflammation,  PGE2   indirectly  exerts  pro-resolution  effects  by 
switching on the transcription of enzymes necessary for the generation of LXs (Levy, 
Clish,  Schmidt,  Gronert  &  Serhan,  2001),  resolvins  (Rvs)  and  protectins  (PDs) 
(Hong, Gronert, Devchand, Moussignac & Serhan, 2003); these represent other 
classes of lipids mediators with pro-resolution properties. 
 
 
 
While PGD2 can elevate cAMP via its DP1, PGD2 may also act independently of its 
DP1 and DP2 receptors when it non-enzymatically dehydrates into prostaglandins of 
the  J2  series  (e.g.  PGJ2,   Δ12 ,14 -PGJ2   and  15-deoxy-Δ1 2 ,1 4 -PGJ2   [15d-
PGJ2]) (Clark, Bishop-Bailey, Estrada-Hernandez, Hla, Puddington & Padula, 2000). 
These cyclopentenone PGs form covalent attachments with reactive sulphydryl 
groups on intracellular  regulatory  proteins,  which  enables  modulation  of  their  
function.  For instance, 15d-PGJ2  upon ligation to the nuclear receptor  PPAR-γ  
(Khan, 1995), decreases pro-inflammatory cytokine release and modifies gene 
expression (Jiang, Ting & Seed, 1998) as well as directly inhibiting the  actions of 
IκB kinase (IKK), 
 which is responsible for the activation of NF-κB (Cernuda-Morollon, Pineda-Molina, 
Canada & Perez-Sala, 2001). 15d-PGJ2, identified in rodent peritonitis resolution 
exudates (Rajakariar et al., 2007), independently of PPAR-γ, can preferentially inhibit 
monocyte rather than neutrophil trafficking through differential regulation of cell- 
adhesion molecule and chemokine expression (Gilroy, Colville-Nash, McMaster, 
Sawatzky, Willoughby & Lawrence, 2003); regulate macrophage activation and pro- 
inflammatory gene expression (Lawrence, 2002); and induce leukocyte apoptosis 
through a caspase-dependent mechanism (Bishop-Bailey & Hla, 1999). Moreover, it 
has been shown that PGD2-derived compounds function as endogenous breaking 
signals for lymphocytes to stimulate resolution (Trivedi et al., 2006).  See Table 1 for 
prostanoids their bio-actions and concentrations at sites of inflammation. 
 
 
 
PROSTANOIDS AND POST-RESOLUTION BIOLOGY 
 
Recently, we demonstrated that classical resolution may not be the end of the local 
immune response to infection/injury, but rather that a third phase subsequent to 
these  exists:   post-resolution   (Motwani   et  al.,   2017).   Traditionally,   resolution 
processes were deemed successful if acute inflammation, as described by leukocyte 
clearance and cytokine catabolism, was terminated; however they may have a 
hitherto   unappreciated   role   in   controlling   adaptive   immune   responses   and 
maintaining tolerance. Specifically, we found that murine innate immune-mediated 
responses  to  low-dose  yeast  cell  wall  extract  (zymosan,  administaered  intra 
perioneally   [i.p.])   or   bacteria    (S.    pneumoniae
ovalbumin-labelled
,   i.p.)   resolved. 
 
Interestingly, these low-dose stimuli elicited a previously overlooked second wave of 
leukocyte influx into tissues that persisted for weeks. These cells comprised three 
separate populations of Ly6chi  monocyte-derived macrophages (MDMs) including 
 CD11B+/CD49d+/CD115+/MHC-II+  myeloid-derived suppressor cells (MDSCs), F4- 
 
80lo/MHC-II+/CD11c+ dendritic cells (DCs) and F4-80int/CD11Bhi/CD11c- 
macrophages. In addition, tissue-resident (embryonic-derived) macrophages, which 
disappear during the acute inflammatory response, re-appear. These diverse 
populations of macrophages were observed alongside lymph node expansion and 
increased numbers of peripheral blood and tissue memory T and B lymphocytes. 
polymorphonuclear (PMNs) were not present during this phase. One of the key 
events in this process is the sustained synthesis of PGE2, which is derived from 
macrophage COX-1/mPGES and that is triggered by IFN. It transpires that this post- 
resolution phase of prostanoid biosynthesis creates a window of susceptibility to 
repeat infections on the one hand, while also controlling local adaptive immune 
processes on the other (Newson et al., 2017). The nature of these 
prostanoid/adaptive immune interactions is being investigated. 
 
 
 
CYTOCHROME P450 
 
Cytochrome P450s (CYP450s) are a family of membrane-bound, haem-containing 
enzymes found in the liver, Kidneys, brain, heart, CV system and lung and are best 
characterized for the catalysis of NADPH-dependent oxidation of drugs, chemicals 
and carcinogens and hormones (Nelson et al., 1996). The CYP450 family contains 
 
57 genes in humans, and although approximately one quarter of these have been 
 
shown capable of metabolizing PUFAs, the CYP2J2 and CYP2C family members 
 
(CYP2C8, 2C9) are thought to be the major enzymes responsible for lipid mediator 
 
production (Bishop-Bailey, Thomson, Askari, Faulkner & Wheeler-Jones, 2014). In 
 
addition to metabolizing AA (Figure 1), CYP450s also readily metabolise the related 
 
6 PUFA linoleic   acid (LA) Figure 2, and 3 PUFAs (see below also) 
 docosahexaenoic acid (DHA, Figure 3) and eicosapentaenoic acid (EPA, Figure 4) 
 
in to series of related biologically active mediators (Smilowitz et al., 2013). CYP450 
 
are capable or metabolizing PUFA substrates by epoxygenase, lipoxygenase and - 
hydroxylase type activities (Zeldin, 2001). The epoxygenase activity inserts a single 
molecular oxygen in to one of the double bonds of each PUFA e.g. for AA to form 
one of 4 regioisomers of epoxyeicosatrienoic acid (5,6-, 8,9-, 11,12- or 14,15-EET; 
the numbers indicating the double bond in AA subject to epoxygenation (Zeldin, 
2001). Each EET can be formed as either an R/S or S/R stereoisomer, with ratios of 
production depending on the generating CYP450. Stereoisomers of EETs may have 
different biological activities, but little research exists to understand the extent if 
these differences. CYP450s can also have lipoxygenase activity producing mid-chain 
(12[R]-),   and   -hydroxylase   activity   producing   terminal   (19[S>R]-,   and   20-) 
 
hydroxyeicosatetraenoic acids (HETEs) (Roman, 2002). Once formed, epoxygenase 
products in particular are quickly metabolized by epoxide hydrolases (EH) or 
reincorporated  in  to  membranes  (Zeldin,  2001).  Soluble  (sEH)  and  microsomal 
(mEH) epoxide hydrolase’s (EH; encoded by the ephx2 and ephx1 respectively) 
combine to metabolize virtually all epoxygenase products in vivo (Edin et al., 2018). 
 
e.g. EETs get converted to dihydroxy-eicosatrienoic acids (DHETs). Importantly, a 
 
number of sEH-inhibitors (sEH-I) have been developed that inhibit the breakdown of 
epoxygenase products to potentiate there signalling (Hwang, Wecksler, Wagner & 
Hammock, 2013). 
 
AA and related PUFA are metabolised by CYP epoxygenase and epoxide hydolases 
in the vascular endothelium (Zhang, Oltman, Lu, Lee, Dellsperger & VanRollins, 
2001) (Roman, 2002), and vascular smooth muscle. In vascular smooth muscle, AA 
 is also catalysed by CYP hydroxylases to 20-HETE (Wang, Guan, Nguyen, Zand, 
Nasjletti & Laniado-Schwartzman, 1999). Indeed, CYP4F3A in myeloid tissue 
catalyzes the ω-hydroxylation of leukotriene B4 to 20-hydroxy leukotriene B4, an 
inactivation process that is critical for the regulation of the inflammatory response 
(Johnson, Edson, Totah & Rettie, 2015). However, it is unknown whether CYP4F3 is 
the source of 20-HETE produced by PMNs (Bednar et al., 2000). These metabolites 
play a large and complex role in maintaining cardiac, renal and pulmonary 
homeostasis by regulating vascular tone and reactivity, ion transport, renal and 
pulmonary functions as well as growth responses (Fleming, 2007). Moreover, they 
have been shown to exert striking anti-inflammatory actions (Inceoglu et al., 2008), 
see below. 
 
 
 
CYTOCHROME P450 AND INFLAMMATION 
 
EETs catalysed by CYPs 2C8, 2C9 and 2J2 inhibit the activation of the transcription 
factor NF-κB via the inhibitor of κB kinase (IKK) (Node et al., 1999). Consequently, 
EETs may therefore have the propensity to down-regulate various cytokine-induced 
pro-inflammatory signalling pathways downstream of NF-κB activation. This may 
explain how EETs prevent the adhesion of PMNs to the vascular wall by suppressing 
the expression of cell adhesion molecules, including intracellular adhesion molecule- 
1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin on the 
surface of endothelial cells in response to cytokines (TNF-α and IL-1α), and LPS 
(Fleming,  2007),  Figure  5.  We  recently  published  that  epoxygenases  are  anti- 
 
inflammatory in human primary monocytes and macrophages (Bystrom et al., 2011), 
 
regulate M1 and M2 phenotype (Bystrom et al., 2011) and promote bacterial and 
 
lipid  phagocytosis  (Bystrom  et  al.,  2013).  In  a  mouse  model  of  inflammatory 
 resolution we took this further using a CYP450 epoxygenase inhibitor SKF525A and 
sEH knockout mice (Gilroy et al., 2016). We reported how CYP450 epoxygenase- 
derived mediators play a crucial role in controlling the infiltration of monocytes into 
sites of inflammation and are essential for the pro-resolution phenotype of cells of 
the monocyte lineage (Gilroy et al., 2016) driving macrophage efferocytosis. 
Additionally, it was recently reported that EETs display analgesic bioactions during 
experimental inflammatory pain (Inceoglu et al., 2008). In general CYP450-derived 
epoxygenase products are anti-atherosclerotic, vasodilatory and anti-inflammatory 
(Chaudhary et al.), with the notable exception of linoleic acid-derived / epoxide 
hydrolase product DiHOMEs. DiHOMEs have recently been shown to mediate 
thermal hyperalgesia (Zimmer et al., 2018), and at high levels are toxic to PMNs, and 
were originally termed ‘leukotoxins’ (Moghaddam, Grant, Cheek, Greene, Williamson 
& Hammock, 1997). 
 
 
 
 
 
 
The use of sEH-Is and sEH knockout mice has been invaluable to understanding the 
in vivo roles or epoxygenase products. Inhibiting sEH has revealed protective roles 
for  epoxygenase  products  in  injury-induced  vascular  neointima  formation 
(Revermann et al.), atherosclerosis and aneurysm formation (Zhang et al., 2009), 
and inflammatory cell recruitment (Gilroy et al., 2016). sEH inhibition or 
overexpression of producing enzymes such as CYP2J2 are also protective in various 
acute inflammatory lung injury models (Revermann et al., 2009). EETs released from 
platelets exert anti-thrombotic properties by inhibiting platelet aggregation induced by 
AA and vascular injury (Briggs, Xiao, Parkin, Shen & Goldman, 2000). EETs can 
also increase the expression of tissue plasminogen activator in a cAMP-dependent 
 mechanism, thus suggesting potentially important roles in controlling the fibrinolytic 
balance at sites of inflammation (Node et al., 2001). 
 
 
 
 
 
The identification of epoxygenase-product receptors has almost exclusively focused 
on arachidonic acid derived- EETs and HETEs, with very little research so far on 
other n3 and n6-PUFA products. Putative receptor targets include transient receptor 
potential (TRP) channels, peroxisome-proliferator-activator receptors, and GRP40 
 
(Bishop-Bailey, Thomson, Askari, Faulkner & Wheeler-Jones, 2014). EETs can 
directly activate PPAR-γ in endothelial cells (Liu et al., 2005) and PPAR- in 
monocytes with EET-mediated anti-inflammatory effects blocked by PPAR-γ (Liu et 
al., 2005) or PPAR- antagonists, respectively. PPAR activation does not however 
account for all the anti-inflammatory effects of EETs. It has been suggested that the 
anti-inflammatory properties of EETs occurred through its ligation to a cell surface 
receptor. It was reported that EETs bind with high-affinity to an ‘EET-receptor’ on the 
surface of a monocytic cell line, belonging to a specific class of GPCRs (Behm, 
Ogbonna, Wu, Burns-Kurtis & Douglas, 2009). GRP40 can be activated by 14,15- 
EET (Ma, Wang, Chen, Zhang, Harris & Chen, 2015). However, it must be noted that 
GRP40 activation only occurred above 10M (Ma, Wang, Chen, Zhang, Harris & 
Chen,  2015);  whereas  most  biological  effects  occur  in  the  nM  range.  These 
receptors are not present in all cells and their known actions don’t always correlate 
with the vascular and anti-inflammatory activities of epoxygenase products. The 
identity of  this receptor  and  its role,  if  any,  in  initiating the  immuno-modulatory 
actions of EETs is yet to be determined. By contrast, intracellular signalling pathways 
are more established. Depending on the model system used, epoxygenases or its 
 products can reduce cellular activation by inhibiting NFB, inhibiting ERK activation, 
elevate cAMP, and/ or induce cellular hyperpolarization (Thomson, Askari & Bishop- 
Bailey, 2012). Recently it has also been proposed that inhibiting inflammatory 
endoplasmic   reticulum   stress   may   be   critical   for   the   beneficial   effects   of 
epoxygenase products, in particular neuropathic pain. 
 
 
 
 
As stated above CYP hydroxylases metabolites also possess anti-inflammatory 
properties.  For instance, 16-HETE can block the adhesion of leukocytes to the 
microvascular  endothelium  (Bednar  et  al.,  2000)  while  also  suppressing  the 
synthesis of LTs as well as inhibiting rises in cerebrospinal fluid pressure, which 
represents index of tissue damage and swelling, in thrombo-embolic model of stroke 
in rabbits (Bednar et al., 2000). Moreover, PMN-derived 20-HETE and 16-HETE also 
counteract TX-induced platelet aggregation (Hill, Fitzpatrick & Murphy, 1992). 
Therefore, it can surmised that not only do metabolites of CYPs maintain CV and 
renal,  but  they  also  regulate  other  diverse  signalling  pathways  pertinent  to 
fibrinolysis, platelet aggregation, inflammation and cellular injury. 
 
 
 
 
LEUKOTRIENE AND LIPOXINS – BIOSYNTHESIS 
 
Lipoxygenase (LOX) enzymes include 5-, 12-, or 15-LOX and are expressed in 
leukocytes, platelets and endothelial cells, respectively. 5-LOX, for instance, 
metabolise AA to the slow-reacting substances of anaphylaxis (LTC4, LTD4  and 
LTE4: potent mediators of the allergic response) (Lewis, Austen, Drazen, Clark, 
Marfat & Corey, 1980) as well as LTB4, a powerful PMN and eosinophil 
chemoattractant (Borgeat & Samuelsson, 1979). 
 To date, four subtypes of LT receptors have been described including B leukotriene 
receptor 1 and 2 (BLT1 and BLT2), and cysteinyl leukotriene receptor 1 and 2 (cys- 
LT1 and cys-LT2). Once bound, LTs a signal via a G-protein in the cytoplasm to 
increase intracellular calcium and block formation of cAMP, which then modulates 
diverse cellular activities ranging from motility to transcriptional activation. While Cys- 
LT1 mediate mucus secretion, oedema accumulation and broncho-constriction in 
airways (Lynch et al., 1999), Cys-LT2 drives inflammatory responses, tissue fibrosis 
in the lung as well as vascular permeability (Beller, Friend, Maekawa, Lam, Austen & 
Kanaoka, 2004). Not surprisingly, Cys-LT1 is overexpressed in patients with chronic 
rhinosinusitis or asthma who have aspirin sensitivity (Sousa, Parikh, Scadding, 
Corrigan & Lee, 2002). By comparison, BLT1 is a high-affinity receptor for LTB4, and 
is responsible for its chemo-attractant and pro-inflammatory properties (Tager & 
Luster, 2003). Although BLT2 acts in a similar fashion to BLT1, LTB4 affinity towards 
BLT1 is much higher. 
 
 
 
In contrast, lipoxins (LXs) are a series of trihydroxytetraene-containing bioactive 
eicosanoids  that  were  first  isolated  from  human  leukocytes  in  the  mid  1980’s 
(Serhan, Hamberg & Samuelsson, 1984). However, in contrast to LTs, which are 
manufactured by intracellular biosynthesis, LXs are generated through cell-cell 
interactions by a process known as transcellular biosynthesis. In different human cell 
types, during the first biosynthetic step of LX biosynthesis, LOX inserts molecular 
oxygen into AA. This can be achieved by two major routes - the first pathway occurs 
in eosinophils, monocytes, or epithelial cells and involves the oxygenation of AA at 
C-15 by 15-LOX yielding 15S-HPETE. Secreted 15S-HPETE is then taken up by 
monocytes or PMNs and converted to 5,6-epoxytetraene by 5-LOX, which is then 
 hydrolysed within these cells by either LXA4 or LXB4 hydrolase to LXA4 or LXB4. 
Activation of this pathway concomitantly reduces LT synthesis, which requires 5-LOX 
to convert AA into LTA4 (Claria & Serhan, 1995). The second major route of LX 
biosynthesis occurs in a LTA4-dependent manner and involves platelet-leukocyte 
interactions. 5-LOX within leukocytes converts AA into LTA4, which when secreted is 
taken up by platelets adhering on the surface of the leukocyte and is subsequently 
transformed to LXA4  and LXB4. This occurs via the LX synthase activity of human 
12-LOX  (Romano  &  Serhan,  1992).  A  third  pathway  of  LX  generation  was 
discovered following aspirin ingestion, which irreversibly acetylates COX-2 in 
endothelial cells and other activated cell types; this is a property specific to aspirin 
and not shared with other NSAIDs. Consequently, instead of COX-2 converting AA 
into PGG2, aspirin acetylation reprograms the enzyme resulting in the transformation 
of AA into 15R-HETE (C-15 alcohol carried in the R-configuration). This is then 
metabolised in a transcellular manner by adherent leukocyte, vascular endothelial or 
epithelial 5-LOX to form 15 epimeric-LX (15-epi-LX) or aspirin-trigged LXs (ATL) that 
carry their C-15 alcohol in the R configuration rather than 15S native LX. Although 
initially thought to be only aspirin triggered, a pathway of endogenous 15-epi-LX 
generation has recently been described, where neuronal sphingosine kinase 1 
mediates this COX-2 acetylation(Lee et al., 2018). ATL’s share many of the immune 
regulatory characteristics of native LXs. 
 
 
 
LIPOXINS – RECEPTORS AND BIO-ACTIONS 
 
The biological actions of LXA4  and 15-epi-LXs are mediated through ALX receptor, 
which is a specific G-protein-coupled receptor (GPCR) isolated and cloned in mouse, 
human and rat tissues (Chiang, Takano, Arita, Watanabe & Serhan, 2003); ALX is 
 also known as the FPRL1 receptor. Human ALX was identified and cloned in various 
leukocytes populations including T cells (Ariel, Chiang, Arita, Petasis & Serhan, 
2003), monocytes (Maddox, Hachicha, Takano, Petasis, Fokin & Serhan, 1997) as 
well as tissue-resident macrophages, synovial fibroblasts (Sodin-Semrl, Taddeo, 
Tseng, Varga & Fiore, 2000) and intestinal epithelial cells (Gronert, Gewirtz, Madara 
& Serhan, 1998). LXA4  and 15-epi-lipoxin A4  (not for LXB4, LTB4, LTD4  or PGE2) 
show high affinity towards ALX (Kd = 1.7nM) [231]. ALX also has the ability to 
interact with other small peptides/proteins such as Ac2-26 and glucocorticoid-derived 
annexin-1, which carry out similar anti-inflammatory effects as LXs and 15-epi-LXs. 
Studies in transgenic mice over-expressing human ALX showed that the protective 
and immune modulatory effects of LXs and 15-epi-LXs were ligand- and receptor- 
dependent (Devchand et al., 2003). In a peritonitis model of zymosan-induced acute 
inflammation,   infiltration   of   neutrophils   was   substantially   diminished   in   ALX 
transgenic mice compared to their wild-type equivalents (Devchand et al., 2003) with 
the site of lipoxin action identified as being the leukocyte/endothelial interface 
mediated by the generation of nitric oxide’s anti-adhesive properties (Paul-Clark, Van 
Cao, Moradi-Bidhendi, Cooper & Gilroy, 2004). 
 
 
 
15-epi-LX analogues also regulate an ALX-dependent p38/MAPK cascade, known to 
promote chemotaxis by inhibiting leukocyte-specific AP-1 phosphorylation and 
activation  (Ohira  et  al.,  2004).  In  addition  to  ALX,  LXs  also  function  as  partial 
agonists to a subclass of rhodopsin receptors (CysLT1) more commonly activated by 
LTs, mediating bioactions in several tissues and cell types other than leukocytes 
(Badr, DeBoer, Schwartzberg & Serhan, 1989). At nanomolar concentrations LXA4 
has been shown to compete for binding with LTD4 on mesangial cells (Badr, DeBoer, 
 Schwartzberg & Serhan, 1989) and human umbilical vein endothelial cells (HUVECs) 
(Fiore, Romano, Reardon & Serhan, 1993) as well as opposing the pro-inflammatory 
effects of LTD4. There is also evidence that another intracellular receptor; the Ah 
receptor  (AhR)  mediates  the  bioactions  of  LXs;  AhR  is  a  ligand  activated 
transcription factor that can trigger such anti-inflammatory events as the expression 
of suppressor of cytokine signalling 2 (SOCS-2) (Aliberti, Serhan & Sher, 2002). 
 
 
 
Lipoxins are anti-inflammatory at nanomolar concentrations controlling both 
granulocyte and myeloid cell entry into sites of inflammation. Indeed, the ability of 
LXs to diminish neutrophil trafficking was corroborated when an analogue of 15-epi- 
LX was intravenously administered to BLT1 knockout mice that have dramatically 
elevated neutrophils in the lungs after high limb ischemia-reperfusion (Chiang, 
Gronert, Clish, O'Brien, Freeman & Serhan, 1999). Furthermore, research in our 
laboratory has uncovered in humans that 15-epi-LXs regulates PMN influx in forearm 
blisters, accounting for low-dose aspirin’s anti-inflammatory properties (Morris et al., 
2009). Our additional work on resolving inflammation has revealed that humans fall 
into two categories, those who resolved their acute inflammatory responses in an 
immediate manner and those that show a more delayed or prolonged healing 
process, with the severity and duration controlled by endogenous epi-lipoxins/ALX 
expression(Morris et al., 2010). Paradoxically, while they inhibit neutrophil and 
eosinophil transmigration (Maddox, Colgan, Clish, Petasis, Fokin & Serhan, 1998), 
lipoxins promote monocyte infiltration into sites of inflammation, which, when 
differentiated into macrophages bring about some of they key aspects of resolution 
and   wound   healing   (Maddox   &   Serhan,   1996)   without   inducing   neutrophil 
 degranulation or release of other reactive oxygen species (Jozsef, Zouki, Petasis, 
Serhan & Filep, 2002).. 
 
 
 
Once at the site of inflammation and resolution, monocyte-derived macrophages are 
stimulated by lipoxins to ingest and clear apoptotic neutrophils (Godson, Mitchell, 
Harvey, Petasis, Hogg & Brady, 2000), which maybe facilitated by changes in the 
actin cytoskeleton (Maderna, Cottell, Berlasconi, Petasis, Brady & Godson, 2002). 
Moreover, lipoxins increase levels of the anti-inflammatory cytokine TGF-β1, which, 
in turn, dampen a range of pro-inflammatory pathways (Bannenberg et al., 2005). 
LXs also anti-fibrotic thereby improve tissue remodelling by reducing the proliferation 
of fibroblasts and mesanglial cells induced by a numbers of factors, including 
connective-tissue growth  factor, platelet-derived growth  factor, TNF-α, LTD4  and 
TGF-β (Leonard et al., 2002). 15-epi-LXs exert the same biological effects as 
endogenously produced LXs, but with additional properties including causing 
increased vasorelaxation (Serhan, 1994) and endothelial cell production of anti- 
inflammatory nitric oxide synthesis (Paul-Clark, Van Cao, Moradi-Bidhendi, Cooper & 
Gilroy, 2004). In addition, 15-epi-lipoxin A4 inhibits TNF-α-induced IL-1β in 
periodontitis in vivo (Hachicha, Pouliot, Petasis & Serhan, 1999), down-regulates 
SOCS-2 signalling (Machado et al., 2006) and dampens TNF-α-induced IL-8 
biosynthesis (Gronert, Gewirtz, Madara & Serhan, 1998). Expectedly, LXs and 15- 
epi-LXs exert beneficial effects in a range of experimental models of inflammation 
and human diseases including cystic fibrosis (Karp, Flick, Yang, Uddin & Petasis, 
2005), glomerulonephritis (Munger et al., 1999), periodontitis (Pouliot, Clish, Petasis, 
Van Dyke & Serhan, 2000), ischemia/reperfusion injury (Chiang, Gronert, Clish, 
O'Brien,  Freeman  &  Serhan,  1999),  various  cutaneous  inflammation  models 
 (Schottelius et al., 2002), pleuritis (Paul-Clark, Van Cao, Moradi-Bidhendi, Cooper & 
Gilroy,  2004),  asthma  (Levy,  Bonnans,  Silverman,  Palmer,  Marigowda  &  Israel, 
2005), wound healing processes in the eye (Gronert, Maheshwari, Khan, Hassan, 
Dunn & Laniado Schwartzman, 2005), colitis, inflammation-induced hyperalgesia in 
rats, as well as microbial infection in mice (Aliberti, Hieny, Reis e Sousa, Serhan & 
Sher, 2002). See Table 1 for SPMs their bio-actions and concentrations at sites of 
inflammation. 
 
 
 
SPECIALISED PRO-RESOLVING LIPID MEDIATORS (SPMs) - BIOSYNTHESIS 
Omega-3 polyunsaturated fatty acids (ω3-PUFA), including eicosapentaenoic acid 
(EPA), docosahexaenoic  acid  (DHA)  are  known  to  maintain  organ function  and 
health but also in reducing severity of inflammatory reactions and incidences of 
infection (Arita et al., 2005b). Although, also now known to be metabolized by COX, 
LOX and CYP450 pathways into distinct lipid mediators, a novel series of ω-3 PUFA 
products were identified in the resolving exudate of a mouse dorsal air pouch or 
peritonitis model using lipidomic and bio-informatic analysis (Lu, Hong, Tjonahen & 
Serhan, 2005). These endogenous mediators are called resolvins (Rvs), protectins 
(PDs) and maresins. 
 
 
 
EPA or DHA generate the Rvs and are categorised as members of the E-series 
(from EPA) or D-series (from DHA). Both series Rvs were initially isolated from 
murine dorsal air pouches treated with EPA or DHA as well as aspirin. Transcellular 
formation of E-series Rvs occurs with the conversion of EPA to 18R- 
hydroxyeicosapentanoic acid (18R-HEPE) by COX-2 expressed within endothelial 
cells treated with aspirin. Similar to 15R-HETE in 15-epi-LX formation, 18R-HEPE is 
 released from endothelial cells to neighboring leukocytes for its conversion by 5-LOX 
to either RvE1 or RvE2, via a 5(6) epoxide-containing intermediate (Arita, Clish & 
Serhan, 2005). This interaction is blocked by selective COX-2 inhibition but not by 
indomethacin or paracetamol (Serhan, Clish, Brannon, Colgan, Chiang & Gronert, 
2000). Although this transcellular route was proposed as the synthetic pathway for 
Rvs, intracellular production of resolvins and maresins have been observed in 
macrophages without the need for transcellular interactions. RvE1 is spontaneously 
produced in healthy subjects with levels increasing after treatment with either aspirin 
or EPA (Arita et al., 2005a). D-series Rvs, aspirin-triggered RvD1 (AT-RvD1) and 
RvD1 are synthesised via a pathway involving sequential oxygenations, initiated by 
15-LOX or aspirin-acetylated COX-2 in the microvascular, respectively, followed by 
 
5-LOX in human neutrophils with an epoxide containing intermediate. For AT-RvD1s, 
DHA is initially converted to epimeric 17R-hydroxydocosahexaenoic acid (17R- 
HDHA). In the absence of aspirin, however, DHA is enzymatically converted to 17S- 
HDHA (Hong, Gronert, Devchand, Moussignac & Serhan, 2003). Interestingly, 
generation of E-series Rvs can also be mediated by microbial and mammalian 
cytochrome P450 enzymes, which convert EPA into 18-HEPE. 18-HEPE can then be 
transformed  by  human  neutrophils  into  either  RvE1  or  RvE2  (Serhan,  Clish, 
Brannon, Colgan, Chiang & Gronert, 2000). Hence, it is possible that microbes at 
sites of infection may contribute to the production of Rvs in a similar pathway. 
 
 
 
DHA is also a precursor for the generation of PDs being enzymatically converted by 
 
15-LOX to a 17S-hydroperoxide-containing intermediate. This intermediate is then 
converted by leukocytes into a 16(17)-epoxide that is subsequently converted in 
these cells to a 10,17-dihydroxy-containing compound (Hong, Gronert, Devchand, 
 Moussignac  &  Serhan,  2003).  PDs  are  distinguished  by  the  presence  of  a 
conjugated triene double bond and by their potent bioactivity. One specific DHA- 
derived lipid mediator, 10,17S-docosatriene was termed protectin D1 (PD1), which 
when generated in neural tissue is called neuroprotectin D1 (NPD1). Moreover, PD1 
exhibits tissue-specific bioactivity as in humans this lipid is synthesised by peripheral 
blood mononuclear cells and Th2 CD4+ T-cells, while in mice it has been isolated 
from exudates and brain cells, human microglial cells (Serhan et al., 2002) and in 
peripheral blood (Hong, Gronert, Devchand, Moussignac & Serhan, 2003). 
 
 
 
SPMs IN INFLAMMATION AND RESOLUTION 
 
One of the broader immunomodulatory properties of RvE1 is its ability to inhibit the 
accumulation neutrophil and dendritic cells at sites of inflammation. This occurs by 
blocking trans-endothelial migration of these cells across the microvascular 
endothelium as well as enhancing their clearance from inflammatory sites (Arita et 
al., 2005a). Other actions of RvE1 includes inhibition of reactive oxygen intermediate 
production from neutrophil in response to bacterial peptide, fMLP and TNFα (Gronert 
et  al.,  2004);  inhibition  of  LTB4-BLT1  signalling  via  NF-κB  and  hence  the 
biosynthesis of pro-inflammatory chemokine and cytokines (Arita, Ohira, Sun, 
Elangovan, Chiang & Serhan, 2007); enhancement of macrophage efferocytosis of 
apoptotic bodies (Schwab, Chiang, Arita & Serhan, 2007); upregulation of the CC- 
chemokine  receptor 5 (CCR5)  on  late  apoptotic  neutrophils  (Ariel  et  al.,  2006), 
which,  in  turn,  abrogates  chemokine  signaling.  RvE1  has  also  been  shown  to 
regulate leukocyte pro-inflammatory cell surface markers including L-selectin, whilst 
selectively disrupting TX-mediated platelet aggregation (Dona et al., 2008), adding 
further insight into its anti-inflammatory/pro-resolution properties. In disease states, 
 RvE1 suppresses Porphyromonas gingivalis-induced oral inflammation and bone 
loss during periodontitis (Hasturk et al., 2006), is protective in trinitrobenzene- 
sulphonic acid-induced colitis in rodents (Arita et al., 2005b) as well as mediating re- 
epithelisation of mouse cornea after thermal-injury (Gronert, Maheshwari, Khan, 
Hassan,  Dunn  &  Laniado  Schwartzman,  2005).  Taken  together,  RvE1  triggers 
various aspects of the pro-resolution cascade ranging from the timely inhibition of 
granulocyte accumulation at sites of inflammation to the efferocytosis or clearance of 
inflammatory debris, reviewed in (Serhan, 2008). 
 
 
 
RvE1 binds to ChemR23 with high affinity (Kd = 48.3nm) resulting in the down- 
regulation of NF-κB activity and consequently pro-inflammatory cytokine synthesis 
such as TNF-α as well as modulating pathways involved in mitogen-activated protein 
kinase (MAPK) signalling (Arita et al., 2005a). Although it has been found in the 
kidney, gastro-intestinal system, brain as well as CV tissue and cells of the myeloid 
lineage, the percentage of ChemR23 expression is highly variable. For example, 
ChemR23 is significantly increased on human monocytes but comparatively less so 
on neutrophils in response to anti-inflammatory mediators such as TGF-β. As with 
ALX, ChemR23 is also receptor for peptide ligands including chemerin, which also 
exerts anti-inflammatory actions (Cash et al., 2008). RvE1 also interacts with the 
LTB4  receptor, BLT1 and  is a partial antagonist  preventing neutrophil activation 
(Arita, Ohira, Sun, Elangovan, Chiang & Serhan, 2007). Therefore, RvE1 couples to 
two distinct receptors to suppress pro-inflammatory mechanisms while enhancing 
pro-resolution pathways. 
 While structurally distinct from RvE1, RvE2 is a second member of the EPA-derived 
family of E-series resolvins. In PMNs from human, it is generated at higher 
concentrations than RvE1, but is equipotent when given intravenously and additive 
when administered alongside RvE1 (Tjonahen et al., 2006). RvE2 also suppresses 
PMN migration into the peritoneum after zymosan (Tjonahen et al., 2006) and it is 
still unclear what receptor RvE2 couples to it is reported to mediate resolution by 
activating  the  chemerin  receptor  ChemR23  and  antagonising  the  LTB4   receptor 
BLT1. 
 
 
 
There are four members of the D-series Rvs including RvD1, RvD2, RvD3 and RvD4 
(Hong, Gronert, Devchand, Moussignac & Serhan, 2003). As with RvE1, RvD1/D2 
exerts both anti-inflammatory and pro-resolution properties by blocking neutrophil 
infiltration, while also enhancing macrophage efferocytosis of apoptotic bodies 
(Krishnamoorthy et al.). The latter occurs via the binding of RvD1 to either ALX or 
GPR32, which are present on the surface of monocytes and PMNs, the expression 
of which is upregulated by inflammatory stimuli including granulocyte-macrophage- 
colony-stimulating factor (GM-CSF) and zymosan (Krishnamoorthy et al.). 
Importantly, in a model of cecal ligation and puncture (CLP) RvD2, whose receptor is 
GPR18(Chiang, Dalli, Colas & Serhan, 2015), in addition to blocking peritoneal PMN 
accumulation markedly reduced bacteria numbers and pro-inflammatory cytokines 
leading to increased animal survival (Spite et al., 2009). 
 
 
 
As already mentioned, in addition to D-series Rvs, DHA also acts as a precursor for 
the synthesis of PDs. PD1, for instance, is synthesised in the human brain, microglial 
(Serhan  et  al.,  2002)  and  peripheral  blood  mononuclear  cells  (Hong,  Gronert, 
 Devchand, Moussignac & Serhan, 2003). As with Rvs, PD1 may also inhibit PMN 
migration as well as toll-like receptor-mediated activation (Duffield et al., 2006) while 
suppressing Th2 inflammatory cytokines and pro-inflammatory lipid mediator 
synthesis (Levy et al., 2007). PD1 also blocks T-cell migration in vivo and promotes 
T-cell apoptosis (Ariel et al., 2005). PD1 is protective in experimental models of 
oxidative  stress  (Mukherjee,  Marcheselli,  Barreiro,  Hu,  Bok  &  Bazan,  2007), 
ischemic stroke (Marcheselli et al., 2003), ischemia-reperfusion renal injury (Duffield 
et al., 2006), asthma (Levy et al., 2007) and Alzheimer’s (Lukiw et al., 2005). Indeed, 
peripheral blood mononuclear cells from Alzheimer’s patients given a DHA-rich 
dietary supplement show dampened biosynthesis of IL-1β, IL-6 and granulocyte- 
colony-stimulating factor (G-CSF) (Vedin et al., 2008). As with RvE2, a receptor is 
yet to be identified. However, it is possible that it couples to a distinct receptor to 
RvE1 as its anti-inflammatory effects are additive with those of RvE1 in vivo. 
 
 
 
Maresins (MaR1 and MaR2) are produced in tissues by macrophages via the actions 
of 12-LOX, through a 13,14-epoxide intermediate (Serhan et al., 2009). MaR1 can 
also be generated at sites of vascular inflammation during human platelet–neutrophil 
interactions via platelet 12-LOX conversion of DHA to 13S,14S-epoxy-maresin, 
followed by neutrophil conversion to MaR1 (Abdulnour et al., 2014). The receptors 
for maresins have yet to be identified. Though maresins have only been recently it 
has been reported that, as with Rvs and PD1, MaR1 block the infiltration of PMNs, 
whilst stimulating macrophage phagocytosis of apoptotic PMNs/zymosan (Serhan et 
al., 2009). 
 SUMMARY 
 
Inflammation  is  a  good  thing;  it  kills  bacteria  and  helps  to  heal  wounds  while 
imparting long term memory against the inciting antigen. Lipids play a key role in 
these events and come in many forms, including those that drive the cardinal signs 
of inflammation and those that help to restrain it and bring the response to a timely 
end. In fact, studying lipids and their inhibitors, NSAIDs, has given us a great deal of 
insight  into  homeostasis,  immune  responses  to  infection/injury  and  the  wound 
healing process. Indeed, inflammatory onset has been an historical point of interest 
for the development of anti-inflammatory drug therapies. Research on the other end 
of the inflammatory spectrum, resolution, has provided the opportunity to harness 
internal mediators and their receptors to help drive on-going inflammation down a 
pro-resolution pathway. Moreover, this is achievable without compromising host 
defence. Such complex manipulation of the immune system provides new 
opportunities to develop further pro-resolution therapies based upon what we have 
learned from studying lipids in this setting. 
 
 
 
FOOTNOTE 
 
 
Nomenclature of Targets and Ligands 
 
 
Key protein  targets  and  ligands  in  this  article  are  hyperlinked  to  corresponding 
entries in http://www.guidetopharmacology.org, the common portal for data from the 
IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018), and are 
permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 
(Alexander et al., 2017). 
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Figure  1.  Cytochrome  p450  metabolism  of  arachidonic  acid  to  EETs  and  their 
subsequent conversion by she to DHETs. 
 
 Figure  2.  Cytochrome  p450  metabolism  of  linoleic  acid  acid  to  EPOMEs  and 
 
DHOMEs 
 
 
 Figure 3. Cytochrome p450 metabolism of DHA to Epoxide docosapentaenoic acids. 
 
 
 Figure 4. Cytochrome p450 metabolism of DHA to Epoxyeicosatetraenoic acids 
 
 
 Figure 5. Biological properties of cytochrome p450 metabolites 
 
 
Table 1. Biological actions  of lipid mediators and their relative  concentrations at 
sites of inflammation 
 
 
